Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1
Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D)...
שמור ב:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | אנגלית |
יצא לאור: |
2015
|
גישה מקוונת: | https://doi.org/10.1001/jama.2015.1328 https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|